JGC
ABVX icon

J. Goldman & Co’s Abivax ABVX Stock Holding History

J. Goldman & Co’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$726K Sell
5,446
-7,303
-57% -$827K 0.02% 501
2026
Q1 		$1.42M Buy
12,749
+9,457
+287% +$1.12M 0.04% 375
2025
Q4 		$444K Sell
3,292
-48,601
-94% -$5.3M 0.01% 465
2025
Q3 		$4.41M Sell
51,893
-15,607
-23% -$957K 0.11% 214
2025
Q2 		$516K Buy
+67,500
New +$440K 0.01% 377

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

J. Goldman & Co's ABVX Position: Q2 2026 in Review

J. Goldman & Co reduced its Abivax (ABVX) stake by 57% in Q2 2026, selling an estimated $827K and leaving 5,446 shares worth $726K. The position accounts for 0.02% of the portfolio, ranked #501.

J. Goldman & Co first reported a position in ABVX in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.41M in Q3 2025. 304 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • J. Goldman & Co held 5,446 shares of Abivax worth $726K as of Q2 2026.
  • J. Goldman & Co sold 7,303 Abivax shares in Q2 2026, an estimated $827K.
  • Abivax made up 0.02% of J. Goldman & Co's portfolio in Q2 2026, its #501 holding.
  • J. Goldman & Co first reported a position in Abivax in Q2 2025 and has held it in 5 quarters since.
  • J. Goldman & Co's Abivax position peaked at $4.41M in Q3 2025.
  • 304 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.